Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. by Isacoff, William H et al.
UCLA
UCLA Previously Published Works
Title
Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, 
Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A 
Retrospective Analysis.
Permalink
https://escholarship.org/uc/item/8725b6g9
Journal
Targeted oncology, 13(4)
ISSN
1776-2596
Authors
Isacoff, William H
Reber, Howard A
Bedford, Rudolph
et al.
Publication Date
2018-08-01
DOI
10.1007/s11523-018-0572-3
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
ORIGINAL RESEARCH ARTICLE
Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin,
nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients
with Advanced Pancreatic Cancer: A Retrospective Analysis
William H. Isacoff1 & Howard A. Reber2 & Rudolph Bedford1 & William Hoos3 & Lola Rahib3 & Alexander Upfill-Brown1 &
Timothy Donahue2 & O. Joe Hines2
Published online: 7 June 2018
# The Author(s) 2018
Abstract
Background Continuous-infusion 5-fluorouracil (5FU) and calcium leucovorin plus nab-paclitaxel and oxaliplatin have been
shown to be active in patients with pancreatic cancer. As a protracted low-dose infusion, 5FU is antiangiogenic, and has synergy
with bevacizumab. As shown in the treatment of breast cancer, bevacizumab and nab-paclitaxel are also synergetic.
Objective In this paper we retrospectively analyze the survival of 65 patients with advanced pancreatic cancer who were treated
with low-dose continuous (metronomic) chemotherapy given in conjunction with conventional anti-VEGF therapy.
Patients and Methods Since July of 2008, we have treated 65 patients with 5FU (180 mg/m2/day × 14 days) via an ambulatory
pump. Calcium leucovorin (20 mg/m2 IV), nab-paclitaxel (60 mg/m2) IVas a 30-min infusion, and oxaliplatin (50 mg/m2) IVas a
60-min infusion were given on days 1, 8, and 15. Bevacizumab (5 mg/kg) IVover 30 min was administered on days 1 and 15.
Cycles were repeated every 28–35 days. There were 42 women and 23 men, and the median age was 59 years. Forty-six patients
had stage IV disease.
Results The median survival was 19 months, with 82% of patients surviving 12 months or longer. The overall response rate was
49%. There were 28 patients who had received prior treatment, 15 of whom responded to therapy. Fifty-two patients had elevated
CA 19-9 prior to treatment. Of these, 21 patients had 90% or greater reduction in CA 19-9 levels. This cohort had an objective
response rate of 71% and a median survival of 27 months. Thirty patients stopped treatment due to disease progression, and an
additional 22 stopped because of toxicity. One patient died while on therapy.
Conclusions This non-gemcitabine-based regimen resulted in higher response rates and better survival than what is commonly
observed with therapy given at conventional dosing schedules. Low-dose continuous (metronomic therapy) cytotoxic chemo-
therapy combined with antiangiogenic therapy is safe and effective.
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Key Points
In our single institution experience treating 65 patients 
with advanced pancreatic cancer, one-year survival in 
our cohort was 82%, substantially higher than has 
been reported in clinical trials of other accepted  
therapies (35-48%).
The lower toxicity of our approach allowed for longer
median duration of treatment compared to other 
accepted protocols.
A reduction in CA19-9 tumor marker levels by 90% or 
greater on therapy was associated with significantly longer
median survival: 28 months versus 15 months.
1 Introduction
Pancreatic ductal adenocarcinoma (PDA) is the third lead-
ing cause of cancer-related deaths in the United States. In
2015, an estimated 48,960 new cases were diagnosed,
which resulted in 40,000 deaths [1]. Despite improved
knowledge regarding the disease and the development of
new targeted and immunologic therapies, along with the
expanded availability of gene profiling, there has been lit-
tle progress with respect to improved outcome. High mor-
tality rates and short survival are explained by the lack of
effective systemic therapies and the fact that most patients
are diagnosed with late-stage disease [2].
Gemcitabine became the standard of care as first-line ther-
apy for patients with metastatic disease, based on the phase III
trial reported by Burris et al., which demonstrated a significant
increase in clinical benefit rate (CBR, an endpoint that mea-
sured overall clinical improvement based on analgesic con-
sumption, pain intensity, performance status, and weight
change) and increased survival and time to disease progres-
sion when compared to 5-fluorouracil (5FU) [3]. More recent-
ly, Conroy et al. reported that a biweekly regimen of infusional
5FU, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX)
was superior to single-agent gemcitabine [4]. Patients who
received FOLFIRINOX had median survival of 11.1 months,
compared with 6.8 months observed for gemcitabine.
Gemcitabine has been combined with a wide variety of che-
motherapeutic drugs and targeted therapies, only to result in
additional side effects and toxicity, without meaningful sur-
vival benefit [5–10]. The one exception is the addition of
nab-paclitaxel to gemcitabine, as reported in October 2013
by VonHoff et al., with median survival of 8.5 and 6.7 months
for nab-paclitaxel plus gemcitabine and gemcitabine alone,
respectively [11]. Apart from FOLFIRINOX and gemcitabine
plus nab-paclitaxel, treatments remain largely ineffective.
Historically, regimens for pancreatic cancer have employed
one, two, or three drugs at their maximum tolerated dose
(MTD). Conventional MTD dosing is characterized by the ad-
ministration of the highest possible dose, followed by a period
of rest. In contrast, a low-dose metronomic (LDM) protocol is
specifically designed to reduce dose-limiting side effects, is
more patient-friendly, and has exhibited substantial rates of
disease control in many adult solid tumors. This approach em-
braces the use of drugs administered at doses that are signifi-
cantly lower than those considered standard, and usually given
over prolonged periods of time, with fewer and shorter breaks
[12]. Many examples of effective metronomic therapies have
been reported in both pediatric and adult oncology [13–17].
In this paper we report the results of a retrospective analysis
of 65 patients with advanced metastatic or locally advanced
incurable pancreatic cancer. All patients received a protracted
infusion of low-dose 5FU combined with nab-paclitaxel, cal-
cium leucovorin, oxaliplatin, and bevacizumab. This
chemotherapeutic regimen was based on rational, scientific
principles of cancer chemotherapy.
5FU is approved for the palliative management of patients
with pancreatic cancer. Low-dose continuous 5FU infusion is
more effective than bolus injections [18]. In a meta-analysis of
1219 cancer patients who received bolus versus infusional
5FU, tumor response was significantly higher in patients treat-
ed with continuous infusion versus bolus (22 vs. 14%), as was
overall survival. Hematologic grade 3 or 4 toxicity was less
common with infusional therapy. By combining oxaliplatin
with infusional 5FU, Ducreux et al. observed higher response
rates and significantly longer survival than with either
infusional 5FU or oxaliplatin alone [19]. Adding irinotecan
and oxaliplatin to infusional 5FU improved outcomes in the
treatment of patients with pancreatic cancer compared to
single-agent gemcitabine [4].
It has been shown that tumor cells that are resistant to che-
motherapy at conventional doses will continue to be sensitive to
low-dose therapy. This observation was first described by
Browder and Klement [20, 21]. 5FU administered continuously
at low doses possesses antiangiogenic properties [22, 23] which
are potentiated when combined with bevacizumab, as seen in
the treatment of colon, gastric, and pancreatic cancers [14,
24–28]. When infusional 5FU, leucovorin, and irinotecan
(FOLFIRI) was combined with bevacizumab, the overall sur-
vival of 31.3 months compared favorably with that of
20.3 months reported with bolus 5FU, leucovorin, irinotecan,
and bevacizumab, and to the 16-month survival reported with
FOLFIRI alone [23]. Paclitaxel and docetaxel given weekly on
a metronomic schedule are less toxic and more active than on
the standard every-three-weeks dosing schedule [29, 30].
Inhibition of tumor angiogenesis by more effective dosing
schedules and targeted inhibitors can enhance the therapeutic
benefit. Elevated serum and tumor vascular endothelial
growth factor (VEGF) levels correlate with poor prognosis
in patients with pancreatic cancer, as do other plasma cyto-
kines and pro-angiogenic factors that have been shown to
predict drug resistance [31–33]. Bevacizumab has been shown
to reverse the angiogenic effects of VEGF, and it can reduce
tumor interstitial pressure, leading to enhanced drug delivery
[34]. Continuous low-dose 5FU may be more effectively
transported than bolus 5FU in an environment of high inter-
stitial pressure [35]. In breast cancer, nab-paclitaxel has been
shown to reach higher intratumoral concentrations and to im-
prove survival compared with standard paclitaxel or docetaxel
[36–38]. When nab-paclitaxel was combined with
bevacizumab, a weekly dosing schedule resulted in higher
progression-free survival (PFS) and overall survival (OS),
with less toxicity, compared with dosing every 3 weeks or
every 2 weeks [39, 40]. The inclusion of bevacizumab in this
regimen may effectively prevent the effects of angiogenesis
while enhancing the activity of both nab-paclitaxel and
continuous-infusion 5FU.
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2 Patients and Methods
2.1 Patients
All patients were treated at the University of California, Los
Angeles (UCLA), in accordance with the Declaration of
Helsinki and Good Clinical Practice Guidelines of the
International Conference on Harmonisation, and were retro-
spectively selected for analysis. This study was approved by
the UCLA Institutional Review Board (approval no. 18–
000192), and the requirement for informed consent was
waived for the entire study. Eligible patients included those
with American Joint Committee on Cancer (AJCC) stage III
locally advanced unresectable pancreatic adenocarcinoma or
stage IV disease, histologically proven ductal or undifferenti-
ated adenocarcinoma, and measurable or evaluable disease.
Patients had Eastern Cooperative Oncology Group
Performance Status of 0–2 and were > 18 years of age. All
patients underwent baseline laboratory studies that included
platelet count > 100,000/mm3, hemoglobin > 9.0 g/dL, abso-
lute neutrophil count > 1500/mm3, ALT/AST < 2.5 times the
upper limit of normal (ULN), total bilirubin < 1.5 times the
ULN, and creatinine < 1.5 mg/dL. No patient initiated treat-
ment until they were 2 weeks beyond surgical bypass proce-
dure or had recovered from surgery. Patients who previously
received prior chemotherapy were included. Patients were ex-
cluded if they had a concurrent second malignancy or known
history of current or previous central nervous system (CNS)
metastatic disease. Pregnant or nursing women were
excluded.
2.2 Drug Dosing
Treatment consisted of 5FU 180 mg/m2/day as continuous
infusion on days 1–15 via an ambulatory chemotherapy pump
into a surgically placed central venous line (IV); nab-paclitax-
el 60 mg/m2 as a 30-min IV infusion, calcium leucovorin
20 mg/m2 IV bolus injection, and oxaliplatin 50 mg/m2 IV
over 60 min on days 1, 8, and 15; and bevacizumab 5 mg/kg
IV over 30 min every other week, on days 1 and 15. Cycles
were repeated every 28–35 days. Treatment was continued
until there was objective evidence of disease progression or
unacceptable treatment-related toxicity, or at the patient's or
physician's discretion.
2.3 Assessments
The primary objective was to quantify the percentage of pa-
tients alive at 1 year. Secondary endpoints included median
survival, response rate, percentage reduction in carbohydrate
antigen (CA)19-9 levels from baseline, and treatment safety.
All patients who completed at least one 15-day cycle of
treatment were evaluated for treatment efficacy and safety.
Safety was assessed by the incidence of treatment-related ad-
verse events (AE) according to the National Cancer Institute
(NCI) Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0, and included grade 3/4 neutropenia
with fever or grade 4 neutropenia lasting ≥ 3 days, any grade
4 hematologic toxicity, grade ≥ 3 thrombocytopenia with
bleeding, or any grade 3/4 treatment-related non-hematologic
toxicity, including vomiting, diarrhea, neuropathy, or
stomatitis.
Response was assessed utilizing Response Evaluation
Criteria In Solid Tumors (RECIST) guidelines. Computed to-
mography (CT) scans were compared against baseline imag-
ing every 8–10 weeks. Serum CA19-9 levels were obtained
each cycle. Overall survival was analyzed using the Kaplan–
Meier method and a stratified log-rank test. Data were cen-
sored for patients who were still alive at the time of analysis.
Survival was calculated from the day of initial therapy to the
date of death or time of last follow-up.
3 Results
3.1 Cohort Characteristics
A total of 65 consecutive patients were treated and evaluated
(Table 1). The median age of the patients was 59 years (range
26–80 years), and 42 patients were women. Nineteen patients
had stage III disease; 46 had stage IV disease. Twenty-eight
patients had undergone prior surgery for their disease. The
median duration of treatment was 29 weeks (range 2–
158 weeks). No patients were receiving chemotherapy at the
time of assessment. Discontinuation of treatment occurred for
the following reasons: all therapy was completed (n = 3), dis-
ease progression (n = 30), toxicity (n = 22), patient and/or
physician discretion (n = 5), or additional adverse events
(n = 5). See Toxicity section for further details.
3.2 Survival and Response
Fifty-three patients (82%) lived 12 months or longer. The over-
all median survival for the entire cohort was 19 months (range
2–91+; Table 2 and Fig. 1a). According to RECIST criteria on
CT or magnetic resonance imaging (MRI), four patients
achieved a complete response and 28 achieved a partial re-
sponse, for a response rate of 49%. Twenty-one patients had
stable disease, resulting in a disease control rate of 81%
(Table 3). Survival was not influenced by either disease stage
at time of diagnosis or whether patients had received prior treat-
ment (Fig. 1b, c; Table 2). Thirteen patients (20%) had normal
CA19-9 levels ( ≥ 36 U/mL) at the time of initial therapy, and
their median survival was 30.5 months, significantly greater
than the overall survival of the 52 patients who had elevated
CA19-9 at start of therapy (17 months) (Fig. 1d). Of the 52
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patients with elevated pretreatment CA19-9, 21 patients had
90% or greater reduction in CA19-9 levels compared with
baseline. This cohort of patients had a response rate of 71%,
with median survival of 28 months, versus 15 months in
patients with less than 90% reduction in CA19-9 (p = 0.004;
Fig. 1e).
Seven patients are alive and being followed off therapy at
the time of analysis. Their survival ranges from 39 months to
120 months since their initial diagnosis. Two remain clinically
free of disease.
3.3 Toxicity
The most frequently observed treatment-related grade 3 or 4
side effects were fatigue (21%), neuropathy (25%), stomatitis
(21%), diarrhea (25%), and nausea and vomiting (9%)
(Table 4).
The most common non-hematologic toxicity was neuropa-
thy, seen in 32 patients (49%), with 16 patients (25%)
experiencing grade 3 or greater. Nineteen patients
discontinued therapy because of neuropathic side effects.
With time, 31 of 32 patients with neuropathy improved to
either grade 1 or 2.
Four patients developed a drug allergy to oxaliplatin, with
three additional patients manifesting interstitial pneumonitis.
All were successfully treated.
Thirteen patients (25%) developed grade 2 or greater hy-
pertension, a known toxicity of bevacizumab. Of these, two
were associated with hemolytic uremic syndrome. Both of
these patients recovered.
Anemia was observed in 14 patients (22%), seven of whom
had grade 3 or greater. Nine patients (14%) developed grade 3
or 4 thrombocytopenia, and 12 patients (18%) had grade 3 or
greater neutropenia.
Additional events included myocardial infarction (n = 1),
hemolytic uremic syndrome (n = 2), and small bowel obstruc-
tion while on therapy (n = 1); all of these patients recovered.
One patient who developedmultiple liver abscesses and sepsis
secondary to cholangitis died while on therapy.
4 Discussion
Advanced, inoperable pancreatic cancer is an aggressive and
rapidly fatal disease. For decades, there has been no clinically
meaningful improvement in survival with therapeutic inter-
vention for patients with metastatic disease. Standard treat-
ments using MTD schedules have been of limited value; thus
an urgent oncologic need remains unmet.
In this paper we have retrospectively analyzed the experi-
ence of 65 patients with advanced, inoperable pancreatic can-
cer who were treated with 5FU as a prolonged infusion in
conjunction with weekly low-dose leucovorin, nab-paclitaxel,
Table 2 Overall survival and survival rates among treated patients
Overall survival All patients
(N = 65)
Stage III
(n = 19)
Stage IV
(n = 46)
Median 19 months 19 months 19 months
Range 2–65+ months 5–42+ months 2–65+ months
Survival rate Number %
6 months 59 90
12 months 53 82
18 months 35 54
24 months 23 41
36 months 12 18
Table 1 Demographic
and baseline clinical
characteristics of patients
who were treated
Characteristics N = 65
Age (years)
Median 59
Range 26–80
Sex
Male 23
Female 42
ECOG Performance Status scorea
0 18
1 27
2 20
Site of primary cancer
Head 29
Body 24
Tail 12
Prior surgery
Yes 28
No 37
Previous chemotherapy
Yes 28
No 37
Disease stage
III 19
IV 46
Site of metastatic disease
Liver 34
Lymph node 13
Lung 6
Peritoneal carcinomatosis 9
Ovary 1
Carbohydrate antigen 19-9 level
Normal 13
Elevated 52
a ECOG = Eastern Cooperative Oncology
Group
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and oxaliplatin. Bevacizumab was added on days 1 and 15.
All analyzed and reported parameters compare favorably to
those observed with more conventional treatments. Patient
survival at 1 year was 82%, with median overall survival of
19 months. Median survival was greater than 27 months for
those patients whose serum CA19-9 level decreased by 90%
or more from pretreatment values. At 24 and 36 months, sur-
vival rates were 41 and 18%, respectively, and 81% of patients
had achieved effective disease control.
We observed that the survival for patients with stage III and
stage IV disease were the same, 19 months. In retrospect,
patients with stage III disease status at the initiation of therapy
may have been inaccurately under-staged, and actually had
Fig. 1 Overall survival of a all
evaluable patients (n = 65), b
stage III (n = 19) and stage IV
(n = 46) patients, c patients who
received prior therapy (n = 28)
and those who did not (n = 37), d
patients with elevated CA19-9
levels (n = 52) and those with
normal CA19-9 (n = 13), and e
patients with elevated CA19-9
with a > 90% decrease in CA19-9
(n = 20) and with a < 90%
decrease (n = 32)
Table 3 Objective response in treated patients
Number of patients
Total evaluable
(N = 65)
Stage III
(n = 19)
Stage IV
(n = 46)
Response results Number % Number % Number %
Complete response 4 6 2 11 2 4.3
Partial response 28 43 8 42 20 43
Stable disease 21 32 8 42 13 28.3
Progression of disease 12 18 1 5 11 24
Disease control 53 81 18 95 35 76
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stage IV cancer. This under-staging results from the inability
of current imaging techniques to detect small-volume metas-
tasis. Previous studies utilizing gemcitabine-based therapies
have reported a difference in survival between stages III and
IV [5–10]. In these studies, there was limited or no therapeutic
impact on survival, and hence survival differences between
stages may be due to a bias in lead time to the discovery of
occult metastases. In our study, median and 1-year survival
rates were substantially higher than those achieved in trials of
other established therapeutic regimens for pancreatic cancer.
In the current work, 1-year survival was 82%, versus 45%
reported for FOLFIRINOX, and median overall survival was
19 months, exceeding the 11.1 months for FOLFIRINOX [4].
With regard to the safety profile, FOLFIRINOX was associ-
ated with a 45% incidence of ≥ grade 3 neutropenia, compared
with 18% in our regimen [4]. We did observe less ≥ grade 3
nausea and vomiting (15 vs. 9%), more ≥ grade 3 diarrhea (25
vs. 13%), and a higher incidence of neuropathy (25 vs. 9%).
Because of the high incidence of neutropenia associated with
FOLFIRINOX, one could speculate that it would be difficult
to build on this regimen. Furthermore, the median duration on
therapy with FOLFIRINOX was less than 16 weeks [4], com-
pared with 29 weeks using a metronomic schedule in the pres-
ent study. Based on response, survival, toxicity, and duration
of treatment, metronomic therapy exhibits a more favorable
therapeutic index.
The regimen reported here also compares favorably to out-
comes achieved with gemcitabine plus nab-paclitaxel. In the
Von Hoff study, median overall survival was 8.5 months, and
1-year and 2-year survival was 35 and 9%, respectively, in the
gemcitabine plus nab-paclitaxel group [11]. By comparison,
median survival, 1-year survival, and 2-year survival reported
here are 19months, 81%, and 41%, respectively. Compared to
the 49% response rate and 81% disease control rate achieved
in the current study, the response and disease control rates for
nab-paclitaxel/gemcitabine were 23 and 48%, respectively.
Finally, the median duration on study for nab-paclitaxel and
gemcitabine was under 18 weeks, substantially less than the
29 weeks observed in the current study.
In spite of the depressing statistics resulting from mostly
negative trials, oncologists continue to accept the marginal
benefits of currently sanctioned therapies for pancreatic can-
cer. Several examples are obvious. One is the establishment of
gemcitabine as the standard of care [41]. Others include the
frequent use of ineffective combinations such as gemcitabine
and erlotinib, gemcitabine and oxaliplatin, or gemcitabine and
cisplatin [5, 10, 42, 43]. There is no conclusive evidence that
these treatment protocols are better than the 5FU-based regi-
mens which were used in the 1980s and 1990s [44].
As stated previously, metronomic dosing may inhibit tumor
angiogenesis, whereas high-dose pulse therapy could potenti-
ate it. Kamen et al. note that the idea of a log-phase dose
survival curve developed by Skipper et al. was a consequence
of an in vivo model used to study the effect of chemotherapy
on cell death [45]. In these models, the dose–response effects
were only valid for cells growing during the log phase. Skipper
et al. clearly indicate that this model would be of limited value
clinically, because growth in solid tumors is not in the log
phase, and the majority of cancer cells within the tumor mass
are non-proliferating during the time of drug exposure [46].
The focus has been on the Bdose^, and has neglected Btime^.
Experimental evidence shows that endothelial cells are affected
by chemotherapy at their MTD [12, 13, 47]. However,
prolonged intervals between treatment allow for tumor re-
growth and endothelial cell repair. The damage to the tumor
endothelium is reversed by a profound rebound in circulating
endothelial progenitor cells (CEPs) released from the bone
marrow during drug-free intervals [48, 49]. This rebound in
CEPs after MTD dosing could explain a potential mechanism
for drug resistance, and thus metronomic dosing may inhibit
this process [48]. Some of the most profound effects have
involved various microtubule inhibitors such as vinblastine,
paclitaxel, and docetaxel [50, 51]. Researchers have proposed
that the pro-apoptotic properties associated with metronomic
chemotherapymay be mediated by the reduction in endothelial
cell specific inhibition by thrombospondin 1 (TSP1) [52, 53].
Other therapeutic agents also have angiogenic Bside effects^
that could work by similar mechanisms. Trastuzumab, a mono-
clonal antibody against ERBB2, was revealed to have
antiangiogenic properties, as it inhibits VEGF expression,
and can induce TSP1 in tumor cells [54–56]. On the other
hand, supportive growth factors such as erythropoietin and
granulocyte colony-stimulating factor (G-CSF) may actually
stimulate angiogenesis, contributing to worse survival out-
comes in some clinical trials [57, 58].
This study is not without limitations. Our work is a retro-
spective analysis of a single institution’s experience spanning
almost 10 years. The lack of randomization precludes a formal
comparison to other treatment modalities, as a standard treat-
ment arm is not available. Because this is a single-institution
Table 4 Common toxicity as a result of treatment
Non-hematologic toxicity, grade ≥ 3 Number (%)
Fatigue 14 21
Neuropathy 16 25
Stomatitis 14 21
Diarrhea 16 25
Nausea/vomiting 6 9
Hypertension (grade ≥ 2) 13 20
Renal failure 2 2
Hematologic toxicity, grade ≥ 3 Number (%)
Anemia 7 11
Thrombocytopenia 9 14
Neutropenia 12 18
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study, there may be additional factors unique to our patient
population that could affect patient survival for which we
could not control. Furthermore, there is notable heterogeneity
in our study population, with a large fraction of patients hav-
ing received prior therapy (chemotherapy and/or surgery) and
a relatively high proportion of confirmed stage IV patients at
treatment initiation.
5 Conclusion
In this report, we demonstrated the feasibility of administering
multi-agent chemotherapy to an unselected patient population,
giving it frequently and for prolonged periods of time, and
observed that it was safe and effective. Metronomic therapy
for pancreatic cancer demonstrated a good therapeutic index
and non-inferiority to the current standard of care. The clinical
experience reported in this retrospective analysis is a safe and
effective option.
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